Odonate Therapeutics, Inc. (ODT) SEC Filing 8-K Material Event for the period ending Tuesday, June 25, 2019

Odonate Therapeutics, Inc.

CIK: 1717452 Ticker: ODT

View differences made from one to another to evaluate Odonate Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Odonate Therapeutics, Inc..


Assess how Odonate Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Odonate Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Odonate Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ODT
CIK: 1717452
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-024077
Submitted to the SEC: Fri Jun 28 2019 4:35:53 PM EST
Accepted by the SEC: Fri Jun 28 2019
Period: Tuesday, June 25, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: